Disc Medicine, Inc.

IRON

US2546041011

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/02/2026 GMT			5-day change	1st Jan Change
79.72 ^USD	+1.77%		+3.10%	+0.39%

01-15	Sector Update: Health Care Stocks Softer Late Afternoon	MT
01-15	Sector Update: Health Care Stocks Softer in Afternoon Trading	MT

Fda pushes back review of Sanofi's diabetes drug Tzield and Disc Medicine's blood disorder drug -documents

Published on 01/15/2026 at 11:03 am GMT

Reuters

Latest news about Disc Medicine, Inc.

01-15	Sector Update: Health Care Stocks Softer Late Afternoon	MT
01-15	Sector Update: Health Care Stocks Softer in Afternoon Trading	MT
01-15	European Stocks Close Mostly Higher in Thursday Trading; GDP Expands in Germany, UK	MT
01-15	Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	MT
01-15	Sanofi, Disc Medicine Drug Reviews Delayed as FDA Flags Safety, Efficacy Issues	MT
01-15	US FDA delays two drug reviews in new voucher program after safety, efficacy concerns	RE
01-15	Fda pushes back review of Sanofi's diabetes drug Tzield and Disc Medicine's blood disorder drug -documents	RE
01-15	Disc Medicine, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 03:00 PM
01-12	Disc Medicine Inc Appoints Lisa Amaya Price as Chief Human Resources Officer	CI
12-17	Disc Medicine Insider Sold Shares Worth $16,858,639, According to a Recent SEC Filing	MT
12-17	Disc Medicine Insider Sold Shares Worth $1,194,372, According to a Recent SEC Filing	MT
12-15	Disc Medicine Insider Sold Shares Worth $3,721,931, According to a Recent SEC Filing	MT
12-07	Disc Medicine, Inc. - Special Call
12-06	Disc Medicine, Inc. Presents Positive Initial Data from Rally-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology Annual Meeting	CI
12-05	Certain Stock Options of Disc Medicine, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.	CI
12-05	Certain Restricted Stock Units of Disc Medicine, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.	CI
12-05	Certain Pre-Funded Warrants of Disc Medicine, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.	CI
12-05	34,694,882 Common Stock of Disc Medicine, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.	CI
11-19	Disc Medicine, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 02:00 PM
11-18	Disc Medicine, Inc. Presents at Stifel 2025 Healthcare Conference, Nov-13-2025 08:40 AM
11-18	Disc Medicine, Inc. Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference, Nov-10-2025 04:30 PM
11-14	Disc Medicine Insider Sold Shares Worth $2,540,923, According to a Recent SEC Filing	MT
11-06	Disc Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-06	Earnings Flash (IRON) Disc Medicine Posts Q3 Net Loss $1.77 a Share, vs. FactSet Est of $1.44 Loss	MT
11-06	Biopharma firm Disc Medicine's Q3 net loss widens	RE

Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Employees

142

Sector

Biotechnology & Medical Research

Calendar

03-26 - Q4 2025 Earnings Release (Projected)

More about the company